$119 Million is the total value of Two Seas Capital LP's 12 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CO | Exit | GLOBAL CORD BLOOD CORPORATIO | $0 | – | -123,800 | -100.0% | -0.40% | – |
| EGRX | Exit | EAGLE PHARMACEUTICALS INC | $0 | – | -45,099 | -100.0% | -1.76% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| HERTZ GLOBAL HLDGS INC | 8 | Q3 2023 | 79.6% |
| ROIVANT SCIENCES LTD | 8 | Q3 2023 | 52.9% |
| ARBUTUS BIOPHARMA CORP | 8 | Q3 2023 | 20.8% |
| ODYSSEY MARINE EXPL INC | 8 | Q3 2023 | 5.5% |
| HERTZ GLOBAL HLDGS INC | 8 | Q3 2023 | 1.0% |
| AMBAC FINL GROUP INC | 7 | Q2 2023 | 4.0% |
| SONOS INC | 7 | Q3 2023 | 5.1% |
| ROIVANT SCIENCES LTD | 7 | Q2 2023 | 1.3% |
| RENREN INC | 4 | Q3 2022 | 15.0% |
| META PLATFORMS INC | 4 | Q3 2023 | 7.9% |
View Two Seas Capital LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| SC 13D/A | 2024-03-29 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2023-11-21 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-05 |
| SC 13D | 2023-10-02 |
| 13F-HR | 2023-08-14 |
View Two Seas Capital LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.